Our results
on the main scientific journals
of the world.
Check the list of papers from NScTI Citrus
Use the filters at the top of the list to select articles by year or by researcher. In the box for each article, use the links ("Summary", "Links", "BibTeX") to open additional information.
PublicationsResearchers
You can use the tag cloud below to select articles by subject.
2022
Assis, Leticia Ribeiro; Theodoro, Reinaldo Dos Santos; Costa, Maria Beatriz Silva; Nascentes, Julyanna Andrade Silva; Rocha, Miguel Divino; Bessa, Meliza Arantes Souza; Menezes, Ralciane Paula; Dilarri, Guilherme; Hypolito, Giovane Böerner; Santos, Vanessa Rodrigues Dos; Duque, Cristiane; Ferreira, Henrique; Martins, Carlos Henrique Gomes; Regasini, Luis Octavio
Antibacterial Activity of Isobavachalcone (IBC) Is Associated with Membrane Disruption Journal Article
In: Membranes, vol. 12, iss. 3, pp. 269, 2022, ISSN: 20770375.
Abstract | Links | BibTeX | Tags: Antibacterial, Biofilm, Chalcone, Membrane, Natural product
@article{nokey,
title = {Antibacterial Activity of Isobavachalcone (IBC) Is Associated with Membrane Disruption},
author = {Leticia Ribeiro Assis and Reinaldo Dos Santos Theodoro and Maria Beatriz Silva Costa and Julyanna Andrade Silva Nascentes and Miguel Divino Rocha and Meliza Arantes Souza Bessa and Ralciane Paula Menezes and Guilherme Dilarri and Giovane Böerner Hypolito and Vanessa Rodrigues Dos Santos and Cristiane Duque and Henrique Ferreira and Carlos Henrique Gomes Martins and Luis Octavio Regasini},
url = {https://www.mdpi.com/2077-0375/12/3/269/htm https://www.mdpi.com/2077-0375/12/3/269},
doi = {10.3390/MEMBRANES12030269/S1},
issn = {20770375},
year = {2022},
date = {2022-01-01},
journal = {Membranes},
volume = {12},
issue = {3},
pages = {269},
publisher = {MDPI},
abstract = {Isobavachalcone (IBC) is a natural prenylated chalcone with a broad spectrum of pharmacological properties. In this work, we newly synthesized and investigated the antibacterial activity of IBC against Gram-positive, Gram-negative and mycobacterial species. IBC was active against Grampositive bacteria, mainly against Methicillin-Susceptible Staphylococcus aureus (MSSA) and MethicillinResistant Staphylococcus aureus (MRSA), with minimum inhibitory concentration (MIC) values of 1.56 and 3.12 µg/mL, respectively. On the other hand, IBC was not able to act against Gram-negative species (MIC > 400 µg/mL). IBC displayed activity against mycobacterial species (MIC = 64 µg/mL), including Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium kansasii. IBC was able to inhibit more than 50% of MSSA and MRSA biofilm formation at 0.78 µg/mL. Its antibiofilm activity was similar to vancomycin, which was active at 0.74 µg/mL. In order to study the mechanism of the action by fluorescence microscopy, the propidium iodide (PI) and SYTO9 fluorophores indicated that IBC disrupted the membrane of Bacillus subtilis. Toxicity assays using human keratinocytes (HaCaT cell line) showed that IBC did not have the capacity to reduce the cell viability. These results suggested that IBC is a promising antibacterial agent with an elucidated mode of action and potential applications as an antibacterial drug and a medical device coating.},
keywords = {Antibacterial, Biofilm, Chalcone, Membrane, Natural product},
pubstate = {published},
tppubtype = {article}
}
Isobavachalcone (IBC) is a natural prenylated chalcone with a broad spectrum of pharmacological properties. In this work, we newly synthesized and investigated the antibacterial activity of IBC against Gram-positive, Gram-negative and mycobacterial species. IBC was active against Grampositive bacteria, mainly against Methicillin-Susceptible Staphylococcus aureus (MSSA) and MethicillinResistant Staphylococcus aureus (MRSA), with minimum inhibitory concentration (MIC) values of 1.56 and 3.12 µg/mL, respectively. On the other hand, IBC was not able to act against Gram-negative species (MIC > 400 µg/mL). IBC displayed activity against mycobacterial species (MIC = 64 µg/mL), including Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium kansasii. IBC was able to inhibit more than 50% of MSSA and MRSA biofilm formation at 0.78 µg/mL. Its antibiofilm activity was similar to vancomycin, which was active at 0.74 µg/mL. In order to study the mechanism of the action by fluorescence microscopy, the propidium iodide (PI) and SYTO9 fluorophores indicated that IBC disrupted the membrane of Bacillus subtilis. Toxicity assays using human keratinocytes (HaCaT cell line) showed that IBC did not have the capacity to reduce the cell viability. These results suggested that IBC is a promising antibacterial agent with an elucidated mode of action and potential applications as an antibacterial drug and a medical device coating.
Assis, Leticia Ribeiro; Theodoro, Reinaldo Dos Santos; Costa, Maria Beatriz Silva; Nascentes, Julyanna Andrade Silva; Rocha, Miguel Divino; Bessa, Meliza Arantes Souza; Menezes, Ralciane Paula; Dilarri, Guilherme; Hypolito, Giovane Böerner; Santos, Vanessa Rodrigues Dos; Duque, Cristiane; Ferreira, Henrique; Martins, Carlos Henrique Gomes; Regasini, Luis Octavio
Antibacterial Activity of Isobavachalcone (IBC) Is Associated with Membrane Disruption Journal Article
In: Membranes, vol. 12, iss. 3, pp. 269, 2022, ISSN: 20770375.
Abstract | Links | BibTeX | Tags: Antibacterial, Biofilm, Chalcone, Membrane, Natural product
@article{nokey,
title = {Antibacterial Activity of Isobavachalcone (IBC) Is Associated with Membrane Disruption},
author = {Leticia Ribeiro Assis and Reinaldo Dos Santos Theodoro and Maria Beatriz Silva Costa and Julyanna Andrade Silva Nascentes and Miguel Divino Rocha and Meliza Arantes Souza Bessa and Ralciane Paula Menezes and Guilherme Dilarri and Giovane Böerner Hypolito and Vanessa Rodrigues Dos Santos and Cristiane Duque and Henrique Ferreira and Carlos Henrique Gomes Martins and Luis Octavio Regasini},
url = {https://www.mdpi.com/2077-0375/12/3/269/htm https://www.mdpi.com/2077-0375/12/3/269},
doi = {10.3390/MEMBRANES12030269/S1},
issn = {20770375},
year = {2022},
date = {2022-01-01},
journal = {Membranes},
volume = {12},
issue = {3},
pages = {269},
publisher = {MDPI},
abstract = {Isobavachalcone (IBC) is a natural prenylated chalcone with a broad spectrum of pharmacological properties. In this work, we newly synthesized and investigated the antibacterial activity of IBC against Gram-positive, Gram-negative and mycobacterial species. IBC was active against Grampositive bacteria, mainly against Methicillin-Susceptible Staphylococcus aureus (MSSA) and MethicillinResistant Staphylococcus aureus (MRSA), with minimum inhibitory concentration (MIC) values of 1.56 and 3.12 µg/mL, respectively. On the other hand, IBC was not able to act against Gram-negative species (MIC > 400 µg/mL). IBC displayed activity against mycobacterial species (MIC = 64 µg/mL), including Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium kansasii. IBC was able to inhibit more than 50% of MSSA and MRSA biofilm formation at 0.78 µg/mL. Its antibiofilm activity was similar to vancomycin, which was active at 0.74 µg/mL. In order to study the mechanism of the action by fluorescence microscopy, the propidium iodide (PI) and SYTO9 fluorophores indicated that IBC disrupted the membrane of Bacillus subtilis. Toxicity assays using human keratinocytes (HaCaT cell line) showed that IBC did not have the capacity to reduce the cell viability. These results suggested that IBC is a promising antibacterial agent with an elucidated mode of action and potential applications as an antibacterial drug and a medical device coating.},
keywords = {Antibacterial, Biofilm, Chalcone, Membrane, Natural product},
pubstate = {published},
tppubtype = {article}
}
Isobavachalcone (IBC) is a natural prenylated chalcone with a broad spectrum of pharmacological properties. In this work, we newly synthesized and investigated the antibacterial activity of IBC against Gram-positive, Gram-negative and mycobacterial species. IBC was active against Grampositive bacteria, mainly against Methicillin-Susceptible Staphylococcus aureus (MSSA) and MethicillinResistant Staphylococcus aureus (MRSA), with minimum inhibitory concentration (MIC) values of 1.56 and 3.12 µg/mL, respectively. On the other hand, IBC was not able to act against Gram-negative species (MIC > 400 µg/mL). IBC displayed activity against mycobacterial species (MIC = 64 µg/mL), including Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium kansasii. IBC was able to inhibit more than 50% of MSSA and MRSA biofilm formation at 0.78 µg/mL. Its antibiofilm activity was similar to vancomycin, which was active at 0.74 µg/mL. In order to study the mechanism of the action by fluorescence microscopy, the propidium iodide (PI) and SYTO9 fluorophores indicated that IBC disrupted the membrane of Bacillus subtilis. Toxicity assays using human keratinocytes (HaCaT cell line) showed that IBC did not have the capacity to reduce the cell viability. These results suggested that IBC is a promising antibacterial agent with an elucidated mode of action and potential applications as an antibacterial drug and a medical device coating.